As promised by Health and Human Services (HHS) Secretary Azar at a briefing on the Trump Administration’s drug pricing blueprint earlier this week, on May 17th, 2018 the Centers for Medicare and Medicaid Services (CMS) notified all Medicare Part D plan sponsors that, “CMS finds any form of ‘gag clauses’ unacceptable and contrary to our efforts to promote drug price transparency and lower drug prices.” The memo
also states, “We also remind Part D plan sponsors that they must require their network pharmacies to disclose any differential between the price of a Part D drug and the price of the lowest cost therapeutically-equivalent generic version of that Part D drug.”
Secretary Azar has made it clear the Administration is committed to taking action to lower prescription drug prices. CMS Administrator Verma and HHS Secretary Azar are committed to ensuring plans do not hide information from patients.
Review the full CMS press announcement here